The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types

2025/06/24 by Gil Awada, Tina Cascone, Michiel S. van der Heijden +3 · 1 voice · 1 citation
Immunology and Microbiology · Medicine · #Bladder and Urothelial Cancer Treatments #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses

paper · doi:10.1038/s43018-025-00990-7

crossref issued 2025/06/24 · crossref published 2025/06/24 · crossref published-online 2025/06/24 · openalex publication_date 2025/06/24 · crossref created 2025/06/24 · crossref deposited 2025/06/26 · openalex created_date 2025/10/10 · crossref indexed 2026/07/27 · openalex updated_date 2026/07/31

Citations

• Pembrolizumab for Early Triple-Negative Breast Cancer
• Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
• Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
• ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
• Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
• Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

Cited by

• Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field

Discussions

• ⭕ How to leverage a tumor - a review on the emerging excitement about neoadjuvant immunotherapy doi.org/10.1038/s430... [bsky, 1 points, 0 comments]